Loading, Please Wait...
RICHLAND, Wash., April 16, 2019 (GLOBE NEWSWIRE) --
(NYSE American: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced a new training collaboration with Texas Oncology. The collaboration brings together the innovators in internal radiation therapy (brachytherapy) to develop a program focused on training the next generation of brachytherapists.
Dr. Bernard Taylor, director of radiation oncology for Texas Oncology, explained the critical need. “Brachytherapy is an extremely important aspect in the treatment of prostate cancer. Prostate cancer patients are being underserved by not having enough physicians with the skills to provide this treatment opportunity. As a physician who has successfully completed thousands of patient brachytherapy implants and a prostate cancer survivor treated with brachytherapy myself, I am professionally and personally committed to enabling physicians to give their patients the best available treatment,” he explained.
The brachytherapy training program will include case observations, practice on artificial prostates, physics planning and real-time procedure methodology. In addition to the training program, Dr. Taylor will host periodic webinars on brachytherapy. The first webinar is set for April 17th and will focus on switching isotopes, which requires no significant adaptation from techniques physicians are now using. Dr. Taylor will be joined by Dr. Atef Omari, medical physicist, Bon Secours Health System Inc.
Dr. Taylor is committed to using Cesium-131 brachytherapy because of the advantages for patients. “I only use Cesium-131 because of the patient benefits. Cesium-131 is a higher energy internal radiation therapy, which means it rapidly delivers a precise dosage of radiation that quickly and aggressively kills cancer cells. Patients also benefit from the rapid dissipation of symptoms. These benefits compared to other isotopes are compelling. In fact, I believe research will ultimately demonstrate that Cesium-131 will make a difference in the treatment of other cancers throughout the body,” he explained.
Isoray CEO Lori Woods said this is an important development for prostate cancer patients and physicians. “Physicians must be given the training to assure that patients have access to the best treatment options. This partnership will make an important contribution in making that access a reality. We are honored to collaborate with Dr. Taylor and Texas Oncology and further our shared commitment to assure the very best care is available to every patient.”
Registration and further information on the webinar, Transitioning Isotopes for Prostate Brachytherapy, is available through this link.
Isoray is the only producer of Cesium-131 brachytherapy, which expands internal radiation treatment for prostate and difficult to treat brain, gynecological, lung, head and neck, esophageal, and abdominal wall cancers.
Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook. Follow us on Twitter @Isoray.
About Texas Oncology
As an independent oncology practice with more than 460 physicians and 210 locations, Texas Oncology’s community-based care offers patients high-quality cancer care without compromise, including access to leading-edge technology, advanced treatment options, and access to clinical trials. As a primary participant in US Oncology Research, Texas Oncology played a role in more than 70 FDA-approved therapies, about one-third of all cancer therapies approved by the agency to date.
Texas Center for Proton Therapy, Texas Breast Specialists, and Texas Center for Interventional Surgery are part of Texas Oncology. Texas Oncology is a member of The US Oncology Network, one of the nation’s largest community-based cancer treatment and research networks. For more information, visit www.TexasOncology.com.
Safe Harbor Statement
Statements in this news release about Isoray's future expectations, including: whether the training collaboration program will be successful, whether the training collaboration program will increase interest in and use of our products will increase or continue, whether use of Cesium-131 in non-prostate applications will continue to increase revenue, whether further manufacturing and production process improvements will be completed or will result in lower costs, whether our market presence and growth will continue, the positive industry data fueling renewed interest in brachytherapy, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released that support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards, the success of our sales and marketing efforts, changes in reimbursement rates, the procedures and regulatory requirements mandated by the FDA for 510(k) approval and reimbursement codes, changes in laws and regulations applicable to our products, the scheduling of physicians who either delay or do not schedule patients in periods anticipated, the use of competitors' products in lieu of our products, less favorable reimbursement rates than anticipated for each of our products, and other risks detailed from time to time in Isoray's reports filed with the SEC. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Media and Public Relations: Sharon Schultz (302) 539-3747 Investor Relations: Mark Levin (501) 255-1910